pharma · Weight management · Short Bowel Syndrome
Zealand Pharma
Zealand Pharma A/S
Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ven
Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Sydmarken 11, Søborg (Copenhagen), 2860, DK
- Founded
- 1998
- Employees
- 596
- Programs
- 18
- Drugs
- 20
- Patents
- 0
Pembrolizumab plus denosumab
Phase 2 · small molecule · Renal Cell Carcinoma, Clear Cell
Pembrolizumab plus denosumab for Renal Cell Carcinoma, Clear Cell is a Phase 2 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).
Internal code ANZUP1601
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zealand Pharma A/S
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Renal Cell Carcinoma, Clear Cell
- Status
- active
- Trials
- 1